Rentosertib: AI-designed drug reports Phase IIa results in pulmonary fibrosis
In the GENESIS-IPF study of 71 patients with idiopathic pulmonary fibrosis at 22 centers (placebo versus three doses, 12 weeks), the 60 mg/day group had a mean FVC change of +98.4 mL versus −20.3 mL for placebo. Groups were small, so larger studies are needed; biomarker analysis was exploratory.
Technology: Pharma.AI (generative AI for targets and molecules)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Phase 2a, multicenter, double-blind, randomized, placebo-controlled, 71 patients for 12 weeks. Primary endpoint (patients with at least one treatment-emergent adverse event) was similar across arms: 70.6% to 83.3%. Treatment-related serious adverse events were low and comparable.
- Still unknown: Efficacy in larger and longer trials is not established by this phase 2a study.
- AI role: Generative AI was used to discover the TNIK target and the small-molecule inhibitor, per the paper's title and abstract.
Evidence sources: https://doi.org/10.1038/s41591-025-03743-2
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 239 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.